Endometrial stromal sarcoma - Observational evidence of a genetic background?

Background: Endometrial stromal sarcomas (ESS) constitute only 0.2% of all gynecological malignancies, and risk factors or genetic associations are largely unknown. We are in contact with more than 100 patients with ESS via an internet support group, and our aim was to analyze the personal and familial medical histories of this large patient group for possible familial cancers aggregations in ESS patients.

Methods: A questionnaire regarding the personal and familial medical history was circulated among the members of the internet group, which was returned by 64 patients.

Results: At diagnosis of ESS the average age was 42 years. Fifty percent had a history of long-term hormonal treatment. One patient each had a previous history of breast carcinoma, thyroid cancer and cutaneous malignant melanoma. One familial case of ESS was observed. At least one malignancy in the family was reported by 47% of patients, and the mother or father were affected in 26%. Multiple familial cancers were observed in 25% of ESS patients. The most frequent familial cancer was breast cancer (25%) followed by endometrial (8%), lung (7%) and prostate carcinoma (5%).

Conclusions: Patients are young, report hormonal treatments and have a familial history of hormone-dependent carcinomas. This suggests a strong genetic predisposition in the oncogenesis of ESS. Patients with ESS may suffer from an inherited genetic predisposition similar to familial breast and prostate carcinoma which may render them susceptible to hormone-dependent growth promotion and/or to cellular damage from particular estrogen metabolites of endometrial cells resulting in a ESS.

Familial cancer; Hormone sensitive tumors; Genetic predisposition; Genetic polymorphism

[1] Chu M.C., Mor G., Lim C., Zheng W., Parkash V., Schwartz P.E "Low-grade endometrial stromal sarcoma: hormonal aspects". Gynecol. Oneal., 2003, 90, 170.

[2] Reich O., Regauer S., Urdl M., Lahousen M., Winter R.: "Estrogen and progesterone receptor content in low-grade-stromal sarcomas". Br. J. Cancer, 2000, 82, 1030.

[3] Beer T.W., Buchanan R., Buckley C.H.: "Uterine stromal sarcoma following tamoxifen-treatment". J. Clin. Pathol., 1995, 48, 596.

[4] Martin-Loeches M., Rius J., Orti R.M.: "Uterine sarcoma associated with tamoxifen use: case report". Eur. J. Gynecol. Oneal., 2003, 24, 202.

[5] Chang K.L., Crabtree G.S., Lim-Tan S.K., Kempson R.L., Hendrickson M.R.: "Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases". Arn. J. Surg. Pathol., 1990, 14, 415.

[6] Walton L.A., Siegfried J.M., Nelson K.G., Siegal G., Kaufman D.G.: "Endometrial stromal cells in culture: an attempt to understand the genesis of biologic activity of uterine sarcomas". Gynecol. Oneal., 1986, 24, 247.

[7] Hendrickson M.R., Tavassoli FA., Kempson R.L., McCluggage W.G., Haller U., Kubik-Huch R.A.: "Mesenchymal tumours and related lesions". In: Tavassoli FA. (ed.), Tumors of the Breast and Female Genital Organs. W HO, Lyon, France, IARC Press, 2003, 233.

[8] Reich O., Regauer S.: "Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study" Mod. Path., 2004, 17, 104.

[9] Goldgar D., Stratton M.R.: "Familial aggregation of cancers of the breast and female genital organs". In: Tavassoli FA. (ed.), Tumors of the Breast and Female Genital Organs, WHO, Lyon, France, IARC Press, 2003, 336.

[10] Briand P., Hou-Jensen K., T horpe S.M., Rose C.: "Hormone dependent uterine sarcomas in GR mice". Eur. J. Cancer, 1981, 17, 635.

[11] Ellis I.O., Schnitt S.J., Sastre-Garau X., Bussolati G., Tavassoli FA., Eusebi V., Peterse J.L. et al.: "Invasive breast carcinoma". In FA. Tavassoli (ed.), Tumors of the Breast and Female Genital Organs, WHO, Lyon, France, 2003, 13.

[12] Press M.F., Scully R.E.: "Endometrial'sarcomas'complicatmg ovarian thecoma, polycystic ovarian disease and estrogen therapy". Gynecol. Oneal., 1985, 21, 135.

[13] Miyoshi Y., Ando A., Hasegawa S., Ishitobi M., Yamarnura J., Irahara N. et al.: "Association of genetic polymorphisms in CYP l 9 and CYP l A l with the oestrogen receptor-positive breast cancer risk". Eur J Cancer, 2003, 39. 2531.

[14] Suzuki K., Nakazato H., Matsui H., Koike H., Okugi H., Kash1-wagi B. et al.: "Genetic polymorphisms of estrogen receptor alpha, CYPI 9, catechol-0-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population". Cancer, 2003, 98, 1411.

[15] Berstein L.M., Imyanitov E.N., Kovalevskij A.J., Maximov SJ., Vasilyev D.A., Buslov K.G. et al.: "CYPl7 and CYP l 9 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity". Cancer Lett., 2004, 207, 191.